Introduction
The measurement of blood pressure (BP) is amongst the most frequently performed clinical investigation. Accurate assessment of BP is essential as unrecognised, systematic errors have the potential to adversely influence treatment in large numbers of patients. A simple error such as undercuffing, for example, overestimates BP by 10-30 mm Hg and it has been estimated that this may incur unnecessary treatment for 300 000 adults in England and Wales at a cost of £12 million pounds per annum. 1 The British Hypertension Society (BHS) protocol for the evaluation of automated devices was developed to enable clinical assessment of any new automated BP device including those being sold for hospital use. 2 Many of the models on the market are inaccurate and it is essential that all new devices be tested by a robust, standardised test. The BHS protocol fulfils this need. The criteria stipulated by the Association for the Advancement of Medical Instrumentation (AAMI) can be incorporated into the BHS methodology. 3, 4 Most published validations have been performed on ambulatory blood pressure measuring (ABPM)
devices but a recent review demonstrated that, of the many ambulatory models available, only 16 have been validated and of these only 12 passed the BHS protocol (at grade B or above) and/or fulfilled the AAMI protocol. 5 The use of ambulatory devices is currently relatively limited, being largely restricted to teaching hospitals and for research purposes. 6 Although automatic and semi-automatic devices are commonly used clinically, the current move to eliminate mercury from clinical areas will create a much larger market for devices used for the routine BP assessment. No stand-mounted oscillometric, automatic device suitable for hospital use has, to our knowledge, been found to be accurate according to a recognised protocol. One of the devices in common use is the Critikon Dinamap. This has been assessed by the BHS validation and in spite of failing with the lowest possible grade (grade D), 7 it remains in use in many hospitals. 8 To our knowledge, the only non-ambulatory oscillometric automatic device with a published BHS validation pass is the Omron 705CP. 9 However, this relatively cheap device is principally designed for casual home use and is unlikely to be sufficiently robust to withstand the rigours of regular clinical measurement.
The Welch Allyn 'Vital Signs' monitor is a compact, bedside monitor, providing non-invasive blood pressure monitoring (NIBPM) by an oscillometric technique. It also has optional capacity for pulse oximetry and temperature reading. In this study we have used the BHS protocol to assess the accuracy of the NIBPM aspects of this monitor.
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Materials and methods
All observers were trained to BHS standards prior to commencement of validation. This involves training and self-assessment by the BHS CD ROM and then comparison between the observers and an expert. Both observers had previously attained this standard, but were reassessed prior to the start of the study, and interobserver accuracy was checked every 20 patients.
Phases one to three
Phases one to three of the BHS protocol require that three devices be calibrated against a mercury sphygmomanometer over 30 readings. These devices must be models produced in the routine production line. The Welch Allyn 'Vital Signs' monitors provided by the manufacturers were calibrated by an automated procedure, according to the instructions in the booklet provided.
After the initial calibration, staff on a busy general medical ward used the three calibrated devices for 6 weeks (the number of readings taken was documented). Following this they were recalibrated, according to phase three of the BHS protocol. Once they had passed the second calibration, one of the monitors was assessed by the static validation procedure (phase 4).
Phase 4
One of the three monitors was selected at random for this phase. The subjects (age 18-84) were recruited from among the staff and patients of a large teaching hospital. The local ethics committee approved the study and all subjects gave written informed consent. Demographic data was collected from the subjects including age, height, weight, gender and arm circumference.
The subjects were asked to sit quietly for a few minutes before the first BP reading was taken and during the sequence of measurements, in a quiet room without telephones. A multi-headed stethoscope was used to enable the two, trained, observers to listen to the mercury sphygmomanometer reading simultaneously. Readings were collected with the subject in the sitting position.
The subjects were recruited in order to fulfil the BP ranges specified in the BHS protocol. Table 1 gives an indication of the minimum number of subjects for each BP group, as defined by the BHS protocol. This has been slightly modified from the BHS protocol giving a lowest systolic range of р100 mm Hg, as our previous experience has demonstrated that subjects with blood pressures р90 mm Hg are prohibitively rare.
An initial reading was taken by the two observers simultaneously, using mercury sphygmomanometry, to obtain a entry BP reading which determines the BP range to which the subject will be allocated (this reading is not used in the analysis). Then sequential BP readings were taken, in the same arm, alternating between the mercury sphygmomanometer and the WA 'Vital Signs' device. The subjects were recruited to give a sample size of 85, which included the minimum numbers with the specified entry BP readings given in Table 1 . The display window of the 'Vital Signs' was obscured, therefore blinding the observers to the readings. The readings were retrieved from the device memory at the end of each procedure (the memory then being cleared). A total of eight recordings made from each individual. One hundred and five individuals were approached in order to fulfil all the entry BP groups.
The data was analysed according to the BHS protocol. The three device readings per subject were compared (a) with the three preceding and (b) then the three subsequent observer readings. Then the set of differences, (a) or (b), which were more favourable to the device, was used to calculate the grading for the monitor. The grading is based on a combination of the cumulative percentages of differences р5, 10 and 15 mm Hg, giving grades A-D, with A and B being a pass. The criteria are described in Table 2 . The grading was calculated separately for systolic and diastolic blood pressure and for each observer. The systolic and diastolic pressures were subsequently analysed again and divided into low, medium and high categories. This reveals if the device has a tendency to under or over estimate BP at the extremes. The AAMI standard is based on the overall mean difference being р5 mm Hg and the standard deviation being р8 mm Hg; these values were calculated from the BHS validation data. Bland-Altman plots were constructed for the better of the two observers to reveal the relationship between the interdevice differences and the mean BP (ie, the mean of the BP measured by both of the devices plotted against the difference between device and observer measurements).
Results
Interobserver differences
The BHS protocol stipulates standards that must be met by the observers. The differences were within the limits required, and are included in Table 2 . 
Grading according to the BHS criteria
The interdevice BP differences obtained for the 85 subjects' gave a total of 255 data points. The grades obtained for the Welch Allyn 'Vital Signs' device for systolic and diastolic BP are given in Table 2 . The standard of accuracy calculated for the Welsh Allyn 'Vital Signs' monitor was an A grade for both systolic and diastolic BP and this standard was maintained at high and low BP levels (see Table 3 ). Bland Altman plots of the data are given for systolic and diastolic BP (Figures 1 and 2 ). These plots illustrate the relationship between the test instrument and the mercury sphygmomanometer readings for the better observer. 10 
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Discussion
This is the first oscillometric, automated device designed for hospital use that has demonstrated adequate accuracy following a recommended protocol. The Welch Allyn 'Vital Sign' monitor is accurate in an adult population over a wide range of blood pressures. The monitor achieved the highest possible grade A, for both systolic and diastolic BP. Very few devices have achieved such accuracy, which uniquely remained consistent over all BP ranges. When the data was divided into low, medium and high BP groups, the monitor achieved an A grade at most levels except for the medium diastolic group in which a B grade was recorded. This is still within acceptable limits for clinical use according to the BHS protocol. This device can therefore be recommended for clinical use. Most of the published validations are for ambulatory devices or for devices intended for home monitoring. The elimination of mercury from clinical areas will create a large market for a reliable robust device that can be used for routine observations and for more intensive monitoring, for example in those patients needing peri-operative care. Environmental and health concerns over mercury exposure have resulted in many hospital trusts, and other organisations, substituting mercury sphygmomanometers for other BP measuring devices. The need for accuracy is of paramount importance both in the correct diagnosis of those in need of treatment as well as providing clinicians with the confidence that patients are not being treated unnecessarily. Any device introduced into clinical areas not only Figure 1 Bland-Altman plot for systolic blood pressure: pressure difference (device minus observer) against the mean of the pressure for the Welch Allyn 'Vital Signs' monitor and measurements by observer 1 (in 85 subjects, n = 255).
Figure 2
Bland-Altman plot for diastolic blood pressure: pressure difference (device minus observer) against the mean of the pressure for the Welch Allyn 'Vital Signs' monitor and measurements by observer 1 (in 85 subjects, n = 255).
should fulfil safety requirements, which are mandatory ('CE' marking), but should also be accurate. For BP measurement this means being equally as good as mercury sphygmomanometry since all epidemiological and clinical knowledge has been based on readings taken using this method.
Compared to many of the devices that have been validated, most of which are ambulatory monitors, the 'LifeSign' did not exhibit the reduction in accuracy at the higher pressures (systolic and diastolic) that is often displayed. Clinical researchers and commercial companies should recognise the need to test the accuracy of this type of device in the future.
